Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule; Transfer of Listing.
On August21, 2017, Axovant Sciences Ltd. (the “Company”) provided written notice to the New York Stock Exchange (“NYSE”) that the Company intends to voluntarily delist its common shares from NYSE, effective as of the close of trading on September5, 2017, and transfer the listing of its common shares to the Nasdaq Global Select Market (“Nasdaq”). Trading on Nasdaq is expected to commence on the next business day, September6, 2017. The Company’s common shares will continue to trade under the stock symbol “AXON.”
A copy of the press release issued by the Company in connection with the transfer of the listing of its common stock from NYSE to Nasdaq is attached hereto as Exhibit99.1 and is incorporated herein by reference.
Item 3.01 Financial Statements and Exhibits.
99.1 Press Release dated August21, 2017.
Axovant Sciences Ltd. ExhibitEX-99.1 2 a17-20701_3ex99d1.htm EX-99.1 Exhibit 99.1 Axovant to Move Stock Exchange Listing to Nasdaq Ticker Symbol to Remain AXON BASEL,…To view the full exhibit click
About Axovant Sciences Ltd. (NYSE:AXON)
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.
An ad to help with our costs